Back to search results

Observational Study of COVID-19 Virus Secretions and Serum

This is an observational study looking at how the COVID-19 virus (SARS-CoV-2) affects people and how their bodies respond. Researchers want to understand the natural course of COVID-19 infections and the health problems that can happen after having COVID-19. They will collect samples like virus secretions (from coughs or sneezes) and blood (serum) from people who have tested positive for COVID-19 or other respiratory viruses. The goal is to learn more about how the virus spreads, how it changes over time, and what factors might predict if someone will have a severe illness or long-lasting symptoms. This information could help develop better ways to prevent and treat COVID-19. You can join if you are between 6 months and 120 years old and have tested positive for COVID-19 or certain other viruses.

Study design
This is an observational study planning to enroll 2000 participants. It is not a treatment study but rather collects information about your health and the virus.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Researchers will look at post-COVID symptoms at 3 months and severe vs. non-severe COVID-19 cases at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04956445

Collection of SARS CoV-2 (COVID-19) Virus Secretions and Serum for Countermeasure Development

Recruiting
Not specifiedAges 6+Observational
Tulane University
~2,000 participants
Updated 2026-05-19 on ClinicalTrials.gov

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
COVID-19 clinically severe vs non severe cases
Measured over 2 Years
+1 more outcome measured

Conditions

Covid19

Explore related trials

Adenovirus InfectionCoronavirus InfectionCOVID-19 InfectionHuman Metapneumovirus InfectionInfluenzaParainfluenzaRhinovirus Infection

Where it's being run

2 sites across 1 states
Louisiana2

Study leadership

  • Dahlene Fusco, MD, PhD · PRINCIPAL_INVESTIGATOR · Tulane University School of Medicine

Who to contact

Dahlene Fusco, MD, PhD
[email protected]
504-988-7316
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

None
Aged under 6 months old
Anemia (Hgb \<7)
Platelet \<80

What this trial measures

  • COVID-19 clinically severe vs non severe cases2 Years

    To determine the clinical and laboratory risk factors which lead to severe vs non-severe COVID-19 clinical course in ambulatory patients. Severe COVID-19 cases defined as death or hospitalized on invasive mechanical ventilation or Extracorporeal membrane oxygenation (ECMO). Non-severe COVID-19 cases defined as hospitalized on non-invasive ventilation or high flow oxygen devices or requiring low flow supplemental oxygen (less than 15L) or not requiring supplemental oxygen, requiring ongoing medical care or no longer requires on going medical care or not hospitalized.

  • Post-COVID symptoms onset at 3 months3 Months

    The proportion (in percentage) of the study cohort exhibiting post-COVID symptoms after recovering from COVID-19 at 3 months from initial date of symptom onset. Post-COVID symptoms which are all new since COVID infection are fatigue, tiredness or exhaustion, muscle aches/muscle pains, pain in joints, problems in sleep, forgetfulness/memory problems, difficulty thinking or concentrating, dizziness or fainting, fever, headache, nausea or abdominal pain, diarrhea, runny nose, sore throat, cough, shortness of breath/abnormal breathing, loss of smell, loss of taste, and inability to walk.